Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tevogen Bio Holdings ( (TVGN) ) has issued an announcement.
On January 30, 2026, Tevogen Bio Holdings announced that its Board of Directors plans to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent on the company achieving future financial milestones such as revenue and earnings targets. Any distribution would depend on Tevogen’s financial performance, capital needs, compliance with solvency requirements under Delaware law, and a final Board determination that a dividend represents the best use of capital at that time, and the company cautioned that there is no assurance a dividend will be declared, nor any certainty regarding its timing or size.
The most recent analyst rating on (TVGN) stock is a Sell with a $0.33 price target. To see the full list of analyst forecasts on Tevogen Bio Holdings stock, see the TVGN Stock Forecast page.
Spark’s Take on TVGN Stock
According to Spark, TipRanks’ AI Analyst, TVGN is a Neutral.
The score is driven primarily by very weak financial performance (no revenue, ongoing losses, negative free cash flow, and negative equity), which outweighs the benefit of lower debt. Technicals add further pressure with a strong downtrend and negative MACD, while valuation metrics offer limited support due to a negative P/E and no dividend yield.
To see Spark’s full report on TVGN stock, click here.
More about Tevogen Bio Holdings
Tevogen Bio Holdings is a socially integrated healthcare company focused on affordable, efficient, and scientifically rigorous solutions, leveraging artificial intelligence and precision T cell therapy platforms to develop advanced, life-saving treatments. Its lead initiative, Tevogen Bio, has completed a proof-of-concept clinical trial for single-HLA-restricted, genetically unmodified allogeneic T cells and maintains a pipeline across virology, oncology, and neurology via its proprietary ExacTcell platform, while its Tevogen.AI unit aims to transform drug development using predictive technologies and cloud-based data services, with the company also exploring future moves into generics, biosimilars, medical devices, and innovative insurance products.
Average Trading Volume: 875,339
Technical Sentiment Signal: Sell
Current Market Cap: $63.02M
For an in-depth examination of TVGN stock, go to TipRanks’ Overview page.